CDC update on gonorrhea: Expand treatment to limit resistance

In all cases, add azithromycin to ceftriaxone or an acceptable alternative agent, and screen asymptomatic individuals at high risk of infection.

Public health efforts have decreased the incidence of gonorrhea over the past several decades, but this progress is threatened by emergent bacteria resistance to the few remaining antibiotics available to treat it.

Gonococcal resistance to penicillin and tetracycline began in the 1970s and was widespread by the 1980s. Resistance to fluoroquinolones developed during the last decade and led the Centers for Disease Control and Prevention (CDC) in 2007 to stop recommending this class of antibiotics for treatment of gonorrhea.1 (See “The decline of gonorrhea: A success story now threatened by antibiotic resistance” on page 737.)

Given the speed with which gonococci developed resistance to fluoroquinolones, the CDC sees as inevitable the eventual development of resistance to cephalosporins—the currently favored agents for gonorrhea.2 This is the main reason behind the new recommendations for treating all cases of gonorrhea with both a cephalosporin and azithromycin, whether or not co-infection with Chlamydia trachomatis is documented or suspected.3

Augment therapy, follow up thoroughly

Family physicians can assist with public health efforts to control gonorrhea and delay the development of cephalosporin resistance by screening for and detecting the infection, diagnosing those with symptoms, and treating according to newer recommendations. It’s also essential to report cases to local public health departments, assist with finding and treating sexual contacts of infected individuals, and immediately report suspected treatment failures.

A 2-drug regimen is imperative. The latest recommendation for treating gonorrhea is ceftriaxone 250 mg IM in a single dose and azithromycin 1 g orally in a single dose. Until 2010, the dose of ceftriaxone had been 125 mg. This dual drug regimen is recommended for several reasons: As with using multiple drugs to treat tuberculosis, it is hoped dual drug therapy will slow development of resistance to both cephalosporins and azithromycin; co-infection with C trachomatis remains a significant problem; and the combination may be more effective against pharyngeal gonorrhea, which is hard to detect.

Alternative regimens. Cefixime 400 mg orally as a single dose is an option in lieu of ceftriaxone, but is not preferred because of the higher number of reported failures of treatment with oral cephalosporins and less efficacy against pharyngeal disease.3 Other injectable cephalosporins are also an option, but less is known about their effectiveness in treating pharyngeal infection. Injectable op-
The latest recommendation for treating gonorrhea is ceftriaxone 250 mg IM in a single dose combined with azithromycin 1 g orally in a single dose.

The decline of gonorrhea: A success story now threatened by antibiotic resistance

The reported rate of gonorrhea rose steadily from the early 1960s until the mid-1970s, when it was close to 500 cases per 100,000. With implementation of the national gonorrhea control program, the annual rate began to fall, and by the mid-1990s it had declined by 74%. Between 1996 and 2006, the rate remained at about 115 cases per 100,000. Between 2006 and 2009, it decreased to the lowest rate since national reporting began, but increased 2.8% between 2009 and 2010 (FIGURE 1).

The highest rates of gonorrhea are in the South (FIGURE 2) and in women ages 15 to 24 and men ages 20 to 24 (FIGURE 3). Rates are highest among blacks (432.5 cases per 100,000), followed by American Indians/Alaska natives (105.7) and Hispanics (49.9). Between 2009 and 2010, gonorrhea rates increased among American Indians/Alaska natives (21.5%), Asians/Pacific Islanders (13.1%), Hispanics (11.9%), whites (9.0%), and blacks (0.3%).

Recent trends in Gonococcus susceptibility to cephalosporins have the CDC concerned. While cephalosporin resistance remains rare, the proportion of Gonococcus isolates that have shown elevated minimum inhibitory concentrations to cephalosporins has increased.

Gonorrhea control depends in part on appropriate screening of individuals at risk (TABLE). Risk factors for gonorrhea include a history of previous gonorrhea infection, other sexually transmitted infections, new or multiple sexual partners, inconsistent condom use, sex work, and drug use. Risk factors for pregnant women are the same as for nonpregnant women. Prevalence of gonorrhea infection varies widely among communities and patient populations.

A gonococcal culture and testing for antibiotic susceptibility should be done for any patient whose symptoms persist after treatment.

FIGURE 1
A decline in gonorrhea that began in the mid-1970s*

*The initiation of a national gonorrhea control program reaped immediate benefits that have continued through the present.

FIGURE 2
Gonorrhea prevalence, 2010


Doing our best in the face of uncertainty
Although evidence is lacking that dual drug therapy will delay the progression of resistance, the strategy makes empirical sense. If gonorrhea develops resistance to cephalosporins, it will seriously challenge public health efforts to control this infection. Family physicians have an important role in controlling this sexually transmitted infection and helping to prevent drug resistance.
USPSTF recommendations on screening for gonorrhea

- The USPSTF recommends that clinicians screen all sexually active women, including those who are pregnant, for gonorrhea infection if they are at increased risk for infection (that is, if they are young or have other individual or population risk factors).
  Rating: B recommendation.*

- The USPSTF found insufficient evidence to recommend for or against routine screening for gonorrhea infection in men at increased risk for infection.
  Rating: I statement.

- The USPSTF recommends against routine screening for gonorrhea infection in men and women who are at low risk for infection.
  Rating: D recommendation.

- The USPSTF found insufficient evidence to recommend for or against routine screening for gonorrhea infection in pregnant women who are not at increased risk for infection.
  Rating: I statement.


*For more on the USPSTF’s grade definitions, see: http://www.uspreventiveservicestaskforce.org/uspsf/gradespre.htm#brec.

References